Celgene And Biogen Earnings Could Make Or Break The Biotech Sector

Celgene And Biogen Earnings Could Make Or Break The Biotech Sector


Celgene and Biogen shares have underperformed the NASDAQ biotech index this year due to concerns about top-line growth and increasing competition. A Leerink analyst warned of a biopharma spillover after J&J reported anemic growth of its pharmaceutical sales in the first-quarter 2017.



from Biotech News